Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioGaia ABBGLAF 100 3-Year Dividend Growth Rate is 39.00% as of Jun. 2026, which is 26% above its 10-year median of 31.05. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $12.60 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 349 Drug Manufacturers companies, BioGaia AB ranks better than 87.39% on this metric.
The historical rank and industry rank for BioGaia AB's 3-Year Dividend Growth Rate or its related term are showing as below:
BGLAF'
s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -27.6 Med: 31.05 Max: 66.4
Current: 39
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of BioGaia AB was 66.40% per year. The lowest was -27.60% per year. And the median was 31.05% per year.
BGLAF's 3-Year Dividend Growth Rate is ranked better than 87.39% of 349
companies
in the Drug Manufacturers industry
Industry Median: 7.7
vs BGLAF: 39.00
During the past 12 months, BioGaia AB's average Dividends Per Share Growth Rate was -15.90% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 39.00% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 27.70% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was 9.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
During the past 13 years, the highest Dividend Payout Ratio of BioGaia AB was 0.73. The lowest was 0.24. And the median was 0.38.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
BioGaia AB Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
SEK 1.640000
2026-05-08
2026-05-11
2026-05-15
Cash Dividend
annually
SEK:USD 0.105915
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
BioGaia AB's Dividend Yield (%) for Today is calculated as
Current Share Price is $11.55.
BioGaia AB's Dividends per Share for the trailing twelve months (TTM) ended in Today is $0.1737006.
During the past 13 years, the highest Dividend Yield of BioGaia AB was 2.85%. The lowest was 0.55%. And the median was 1.03%.
Warning Sign:
BioGaia AB stock Dividend Yield % is close to 2-year low.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB 3-Year Dividend Growth Rate Related Terms>
BGLAF vs ZTS: 3-Year Dividend Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB 3-Year Dividend Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's 3-Year Dividend Growth Rate distribution charts can be found below:
* The bar in red indicates where BioGaia AB's 3-Year Dividend Growth Rate falls into.
BioGaia AB 3-Year Dividend Growth Rate Calculation
This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Dividend Growth Rate of 39.00% mean?
BioGaia AB (BGLAF) has a 3-Year Dividend Growth Rate of 39.00% as of Jun. 2026. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on BioGaia AB and its competitors. This is 26% above median its historical median of 31.05. According to the industry distribution chart, BioGaia AB ranks #44 out of 349 companies in the Drug Manufacturers industry, placing it in the top 12.6%.
Is BioGaia AB's 3-Year Dividend Growth Rate too high?
BioGaia AB's current 3-Year Dividend Growth Rate of 39.00% is 26% above median its 10-year median of 31.05. The Drug Manufacturers industry median 3-Year Dividend Growth Rate is 7.70. BioGaia AB's value of 39.00% is 406.5% above this industry median. Based on the distribution chart, BioGaia AB ranks #44 out of 349 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's 3-Year Dividend Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #44 out of 349 companies for 3-Year Dividend Growth Rate. This places BioGaia AB in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year Dividend Growth Rate is 7.70. BioGaia AB's value of 39.00% is 406.5% above this benchmark. While the company's 10-year median is 31.05 vs. the industry median of 7.70, BioGaia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Dividend Growth Rate for a Drug Manufacturers company?
The median 3-Year Dividend Growth Rate among Drug Manufacturers companies is 7.70, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Dividend Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Dividend Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current 3-Year Dividend Growth Rate of 39.00% is 406.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Dividend Growth Rate mean?
A high 3-Year Dividend Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median 3-Year Dividend Growth Rate is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current 3-Year Dividend Growth Rate is 39.00%, which is 26% above median its own 10-year median of 31.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BGLAF) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.60, compared to a current price of $11.55 — trading 8.3% below its estimated fair value. The current 3-Year Dividend Growth Rate is 39.00%, which is 26% above median its 10-year median of 31.05 and 406.5% above the Drug Manufacturers industry median of 7.70. BioGaia AB's overall GF Score™ is 100/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Dividend Growth Rate calculated?
3-Year Dividend Growth Rate is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current 3-Year Dividend Growth Rate is 39.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $11.55 is trading 8.3% below its estimated GF Value™ of $12.60.
GuruFocus considers BioGaia AB to be Modestly Undervalued.
Key valuation signals for BGLAF:
3-Year Dividend Growth Rate: 39.00% (26% above median its 10-year median of 31.05)
GF Value™: $12.60 vs. price of $11.55 (8.3% below fair value)
Industry Position: 406.5% above the Drug Manufacturers median (#44 of 349)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
3-Year Dividend Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
